<DOC>
	<DOCNO>NCT01183468</DOCNO>
	<brief_summary>The drug Alpha-1 Antitrypsin ( AAT , Aralast NP ) test study anti-inflammatory drug ( medication decrease inflammation , part body 's normal ability fight infection respond injury ) affect cell think involve development type 1 diabetes mellitus ( T1DM , T1D ) . All subject enrol study new-onset T1DM ( diagnosis T1DM within 100 day Visit 0 ; T1DM diagnosis fulfil American Diabetes Association standard T1DM criterion ) . The focus Part I trial ( NCT01183468 ) pharmacokinetics ( PK ) , pharmacodynamics ( PD ) safety . Upon completion Part I , include satisfactory safety review , enrollment Part II ( NCT01183455 , Phase II Clinical Trial ) begin .</brief_summary>
	<brief_title>A Research Trial Aralast New Onset Diabetes ( RETAIN )</brief_title>
	<detailed_description>Researchers interested conduct study ass whether Aralast NP ( AAT , Alpha-1 Antitrypsin ) help slow progression T1DM . Part I study two part : -1a -1b : Part 1a ( Complete ) : An open-label , dose-escalation , PK , PD safety study . Participants receive 12 intravenous ( IV ) infusion Aralast NP . Infusions 1 6 administer 45 mg/kg/wk infusion 7 12 administer 90 mg/kg/wk . Part Ia consist two group : - Subjects age 16 - 35 year enrollment new-onset T1DM - Subjects age 8 -15 year enrollment new-onset T1DM . Part 1b ( study terminate prior subject enrollment ) : An open-label , dose-escalation PK , PD safety study participant receive 12 infusion Aralast NP . Infusions 1 6 administer 90 mg/kg/wk infusion 7 12 administer 180 mg/kg/wk . Part Ib consist two group : - Subjects age 16 - 35 year enrollment new-onset T1DM - Subjects 8 - 15 year enrollment new-onset T1DM . Participants Part Ib roll Part II ( Refer NCT01183455 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Diagnosed T1DM within past 100 day ( enrollment ) Positive least one diabetesrelated autoantibody ( AntiGAD ; Antiinsulin , obtain within 10 day onset insulin therapy ; IA2 antibody and/or ICA , ZnT8 . ) Peak stimulate Cpeptide level &gt; 0.2 pmol/mL follow mixed meal tolerance test ( MMTT ) Severe active disease ( chronic active hepatitis ; cardiac , pulmonary disease , hepatic , renal immunodeficiency ) History bleed clot factor deficiency , stroke History vascular disease significant vascular abnormality Positive serology exposure ( hepatitis B virus ) HBV , HCV ( hepatitis C virus ) , HIV ( human immunodeficiency virus ) toxoplasmosis Clinically active infection EBV ( EpsteinBarr virus ) , CMV ( cytomegalovirus ) , tuberculosis ( TB ) Prior current use oral , inhaled intranasal glucocorticoid , medication know cause significant , ongoing change course T1DM immunologic status Prior treatment Alpha 1Antitrypsin ( Aralast NP , AAT ) hypersensitivity alpha 1antitrypsin human plasmaderived product Current prior ( within last 30 day ) use metformin , sulfonylurea , glinides , thiazolidinediones , exenatide , liraglutide , DPPIV inhibitor amylin Current use medication know influence glucose tolerance ( e.g. , betablockers , angiotensinconverting enzyme inhibitor , interferon , quinidine antimalarial drug , lithium , niacin ) Females pregnant lactating , unwilling defer pregnancy study participation IgA ( immunoglobulin A ) deficiency Uncontrolled hypertension Current lifethreatening malignancy Any condition investigator 's opinion may compromise study participation may confound interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 1 ( new-onset )</keyword>
	<keyword>Diabetes Mellitus , Insulin-Dependent ( new-onset )</keyword>
	<keyword>new-onset T1DM</keyword>
	<keyword>new-onset T1D</keyword>
	<keyword>Diabetes Mellitus , Juvenile-Onset</keyword>
	<keyword>Diabetes , Autoimmune</keyword>
	<keyword>Aralast NP</keyword>
	<keyword>Alpha-1 Antitrypsin</keyword>
	<keyword>AAT</keyword>
</DOC>